Definition
Mericitabine is an investigational nucleoside analogue that functions as an inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. It has been studied in clinical trials for the treatment of chronic HCV infection but has not received regulatory approval for clinical use.
Overview
Mericitabine, also designated as RG‑1626, was developed by the pharmaceutical company Roche. As a prodrug, it is metabolized intracellularly to its active triphosphate form, which competes with natural nucleotides for incorporation into the viral RNA chain, leading to premature termination of viral replication. Early‑phase studies demonstrated antiviral activity against multiple HCV genotypes, and it was evaluated both as monotherapy and in combination with other direct‑acting antivirals (DAAs). Despite initial promise, later clinical development was discontinued, and the compound has not progressed to registration.
Etymology / Origin
The name “mericitabine” follows a convention common to nucleoside analogues, where the suffix “‑tabine” (or “‑citabine”) denotes a cytidine‑derived scaffold. The prefix “meri‑” likely reflects a proprietary naming sequence assigned by the developer rather than a linguistic root with a defined meaning. Precise rationale for the prefix has not been publicly disclosed.
Characteristics
| Property | Details |
|---|---|
| Chemical class | Nucleoside analogue (cytidine‑like) |
| Mechanism of action | Inhibits HCV NS5B polymerase by chain termination after intracellular phosphorylation to the triphosphate form |
| Pharmacokinetics | Administered orally; undergoes hepatic metabolism to the active triphosphate; elimination primarily renal |
| Clinical status | Investigational; Phase II trials completed; development discontinued |
| Regulatory status | Not approved by FDA, EMA, or other major health authorities |
| Related compounds | Sofosbuvir, dasabuvir, ribavirin – other agents targeting HCV replication |
Related Topics
- Hepatitis C virus (HCV) – A positive‑sense RNA virus causing chronic liver disease; target of many antiviral therapies.
- NS5B polymerase inhibitors – A class of DAAs that block the viral RNA‑dependent RNA polymerase, essential for viral genome replication.
- Direct‑acting antivirals (DAAs) – Medications that target specific HCV proteins, revolutionizing treatment outcomes.
- Roche (pharmaceutical company) – Developer of mericitabine and numerous other antiviral agents.
Note: While mericitabine has been referenced in peer‑reviewed literature and clinical trial registries, detailed pharmacological data remain limited due to the cessation of its development.